:: Volume 10, Issue 3 (Int J Mol Cell Med 2021) ::
Int J Mol Cell Med 2021, 10(3): 163-180 Back to browse issues page
Curcumin in Combination with Other Adjunct Therapies for Brain Tumor Treatment: Existing Knowledge and Blueprint for Future Research
Kavita Peter1 , Santosh Kumar Kar2 , Ragini Gothalwal1 , Puneet Gandhi 3
1- Department of Biotechnology, Barkatullah University, Bhopal, M.P, India.
2- Nano Herb Research Lab, KIIT-TBI, Bhubaneshwar, Odisha, India.
3- Department of Research, Bhopal Memorial Hospital and Research Centre, Bhopal, M.P, India. , puneetgandhi67@yahoo.com
Abstract:   (1223 Views)
Malignant brain tumors proliferate aggressively and have a debilitating outcome. Surgery followed by chemo-radiotherapy has been the standard procedure of care since 2005 but issues of therapeutic toxicity and relapse still remain unaddressed. Repurposing of drugs to develop novel combinations that can augment existing treatment regimens for brain tumors is the need of the hour. Herein, we discuss studies documenting the use of curcumin as an adjuvant to conventional and alternative therapies for brain tumors. Comprehensive analysis of data suggests that curcumin together with available therapies can generate a synergistic action achieved through multiple molecular targeting, which results in simultaneous inhibition of tumor growth, and reduced treatment-induced toxicity as well as resistance. The review also highlights approaches to increase bioavailability and bioaccumulation of drugs when co-delivered with curcumin using nano-cargos. Despite substantial preclinical work on radio-chemo sensitizing effects of curcumin, to date, there is only a single clinical report on brain tumors. Based on available lab evidence, it is proposed that antibody-conjugated nano-curcumin in combination with sub-toxic doses of conventional or repurposed therapeutics should be designed and tested in clinical studies. This will increase tumor targeting, the bioavailability of the drug combination, reduce therapy resistance, and tumor recurrence through modulation of aberrant signaling cascades; thus improving clinical outcomes in brain malignancies.
Keywords: Glioblastoma, polyphenol, combination therapy, resistance, sensitization, synergistic
Full-Text [PDF 565 kb]   (212 Downloads)    
Type of Study: Review | Subject: Cancer
Received: 2021/07/19 | Accepted: 2022/01/3 | Published: 2022/01/10

XML     Print

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 10, Issue 3 (Int J Mol Cell Med 2021) Back to browse issues page